10-K: Retractable Technologies Faces Tariff Headwinds, Reports Net Loss

Retractable Technologies, Inc. reported a net loss of $12.57 million for fiscal year 2025, impacted by significant tariffs on Chinese imports and material weaknesses in internal controls, despite increased domestic and international sales.

Summary

• Net loss increased to $12.57 million in 2025, compared to $11.89 million in 2024 and $7.01 million in 2023.
• Total revenues increased by 15.8% to $38.27 million in 2025 from $33.05 million in 2024.
• Domestic sales increased 9.7% in 2025, primarily due to VanishPoint and EasyPoint needle sales, while international revenues increased 64.0% but with discounted pricing.
• Gross profit margin improved to 0.1% in 2025 from (3.1)% in 2024.
• Approximately $1.8 million in tariff expense was incurred in 2025.
• Material weaknesses were identified in internal controls over the monthly close process and account reconciliations as of December 31, 2025.
• Market capitalization was $23.1 million as of December 31, 2025, while total stockholders' equity was $74.4 million.
• The U.S. Supreme Court ruled in February 2026 that IEEPA tariffs exceeded presidential authority, but Section 301 tariffs (100%) on syringes and needles from China remain, with an additional 10% ad valorem duty effective February 20, 2026, resulting in a 120% tariff rate on most syringe and needle products from China.
• The company is shifting manufacturing of 1mL, 3mL, and EasyPoint needles to its domestic facility to mitigate tariff impacts.
• A $1.9 million settlement payment was received in May 2025 from litigation with former legal counsel.
• Cash flow used by operations was $7.1 million in 2025.
• The investment portfolio held $34.4 million in debt and equity securities as of December 31, 2025, representing 24.1% of total assets, with an unrealized loss of $5.0 million but a realized gain of $5.6 million from sales.
• Inventory write-downs of approximately $2.2 million and an impairment charge of $954 thousand were recorded in 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a challenging period for the company, marked by increasing net losses, significant tariff burdens, and internal control weaknesses, despite some revenue growth and strategic efforts to mitigate import reliance.

Positives

• Total revenues increased by 15.8% to $38.27 million in 2025, with domestic sales up 9.7% and international sales up 64.0%.
• Gross profit margin improved to 0.1% in 2025 from a negative (3.1)% in 2024.
• A $5.6 million gain was realized from the sale of debt and equity securities in 2025.
• A $1.9 million settlement payment was received from litigation in May 2025.
• Increased domestic manufacturing capacity for vaccine-related products, funded in part by an $81.0 million Technology Investment Agreement (TIA) with the U.S. government.
• Existing equipment was adapted to produce 0.5 mL syringes domestically, aiming to eliminate reliance on imports for these products by the second half of 2026.
• The company maintains a strong balance sheet with total stockholders' equity of $74.4 million as of December 31, 2025.
• No material legal proceedings were ongoing as of March 9, 2026.
• A robust cybersecurity program is in place, featuring a layered approach, regular risk assessments, and an experienced Information Security Officer.

Negatives

• Reported a net loss of $12.57 million in 2025, an increase from $11.89 million in 2024.
• Operating loss remained high at $21.18 million in 2025, similar to $21.11 million in 2024.
• A significant tariff expense of approximately $1.8 million was incurred in 2025.
• The prevailing tariff rate on most syringe and needle products imported from China was 120% as of March 9, 2026.
• Material weaknesses were identified in internal controls over the monthly close process and account reconciliations.
• Cash flow used by operations was $7.1 million in 2025.
• An unrealized loss on debt and equity securities of $5.0 million was recognized in 2025.
• Inventory write-downs of approximately $2.2 million and an impairment charge of $954 thousand were recorded in 2025.
• The stock price reached a low of $0.62 per share in 2025, and management is concerned it is not correlated with the company's value.
• Domestic customers have excess product inventory, leading to decreased demand, with an uncertain timeline for depletion.
• The company relied on Chinese manufacturers for 62.6% of its products in 2025, with some products exclusively sourced from China.
• Liquidity is expected to decline materially over the next 1-3 years due to tariffs and increased domestic manufacturing costs.
• High concentration of ownership by CEO Thomas J. Shaw (55.7%) could delay or prevent changes in control and presents potential conflicts of interest.

Risks

• Continuing material negative impact on results of operations and financial position due to tariffs (120% on syringes/needles from China as of March 9, 2026) and reliance on Chinese manufacturers for 62.6% of products in 2025.
• Concern that the stock price ($0.77 per share, $23.1 million market cap as of Dec 31, 2025) does not reflect the company's value ($74.4 million stockholders' equity).
• Domestic customers have retained products for vaccination purposes in inventory, leading to decreased demand, with an uncertain timeline for depletion.
• Dependence on patent rights, with risks of invalidation or circumvention, and potential significant sales loss when VanishPoint patents expire (2028-2032).
• Vulnerability to the development of superior competing products and changes in technology (e.g., GLP-1 based treatments) due to a narrow product focus.
• Fierce competition from larger, more established companies like Embecta Corp., which possess significantly greater financial resources and market influence.
• CEO Thomas J. Shaw controls 55.7% of outstanding Common Stock, influencing operations and governance, potentially creating conflicts of interest.
• Defensive measures, including an amendment to the Technology License Agreement, grant CEO Thomas J. Shaw unilateral termination rights or license conversion following a hostile takeover.
• Increased reliance on the domestic supply chain for raw materials and components, with risks of disruptions from geopolitical conflicts (e.g., Middle East) or supplier issues.
• Inflationary price pressures and uncertain availability of commodities, raw materials, utilities, labor, or other inputs could lead to higher production and shipping costs that may not be recoverable.
• Public sentiment and acceptance of vaccinations, as well as U.S. public health policy, could negatively impact demand for vaccine administration products.
• Inherent business risk of exposure to product liability claims and potential damage to reputation from product defects.
• Changes in healthcare regulatory requirements, reimbursement programs, or patient access to healthcare could adversely affect demand and pricing.
• Investment portfolio (24.1% of total assets) is subject to market risk, with potential for fluctuations in value and liquidity.
• Future health crises could lead to temporary closures, supply chain disruptions, and negative economic impacts affecting sales and operating results.
• Risk of transaction errors, processing inefficiencies, loss of customers, business disruptions, or loss of intellectual property due to critical information system disruptions or security breaches, including reliance on external vendors.
• Illegal distribution and sale of counterfeit versions of products could harm reputation and business, and product diversion may reduce revenues.

Future Outlook

Tariffs are expected to have a continuing material impact on the company's ability to source finished goods and certain raw materials/component parts, and on its results of operations and financial position, with uncertainty remaining regarding future tariff rates. The company anticipates incurring higher manufacturing costs in the near term as it increases domestic production and seeks efficiencies. Commercial quantities of domestically produced 0.5 mL syringes are expected in the second half of 2026. Domestic demand is projected to remain depressed due to existing customer inventory, with an unclear timeline for depletion. Changes in public sentiment towards vaccinations could materially impact the business, and no new products under development are expected to be commercially available in 2026. The regulatory environment is expected to continue requiring significant effort and investment for compliance. Liquidity is projected to decline materially over the next 1-3 years, though management believes it can meet long-term cash requirements through existing cash and investment liquidation.

Management Comments

• "We continue working to lessen the financial impact of the tariffs through strategic ordering of products from our Chinese suppliers and shifting a larger portion of manufacturing of 1mL, 3mL, and EasyPoint needles to our domestic manufacturing facility."
• "We believe domestic customers may have retained product provided for vaccination purposes in inventory, leading to a decrease in overall demand. The extent to which these supplies still exist and the effect they have on future ordering patterns is difficult to estimate."
• "As foreign trade policy continues to evolve, including the impact of the Supreme Court's ruling, uncertainty as to future tariff rates and affected products remains."
• "We are concerned that our stock price is not correlated with our value."
• "We believe we will have adequate means to meet our short-term needs to fund operations for at least 12 months from the date of issuance of the financial statements."
• "We believe we will have adequate means to meet our currently foreseeable long-term liquidity needs, although the tariffs and our costs related to an increase in domestic manufacturing will increase our expenses materially."
• "Management identified the following material weaknesses in internal controls as of December 31, 2025: The Company's controls over the monthly close process and account reconciliations were not operating at a level of precision to prevent or detect misstatements in a timely manner."
• "Management intends to enhance its controls over the monthly close process and account reconciliations."

Industry Context

StockSavvy.ai notes that the medical device industry, particularly for consumables like syringes and needles, is highly competitive and subject to significant regulatory oversight and geopolitical influences. The company's struggle with tariffs on Chinese imports reflects a broader trend of supply chain re-evaluation and reshoring efforts in critical healthcare sectors, driven by national security and economic policy. The continued dominance of larger players like BD and Embecta highlights the challenges smaller companies face in gaining market share, even with innovative safety features. The impact of vaccine hesitancy and changes in public health policy also represents a significant external factor for companies reliant on vaccination-related product lines.

Comparison to Industry Standards

• The company faces formidable competition from much larger and more established companies like Becton, Dickinson and Company (BD) and Embecta Corp.
• Embecta, specializing in diabetes management, reported 1,850 employees in 2025, significantly larger than Retractable Technologies' 201 employees.
• Retractable Technologies competes on healthcare worker and patient safety, product performance, and quality, believing its products are highly effective safety devices.
• VanishPoint 1mL syringes meet pharmaceutical manufacturers' criteria for low dead space, a competitive advantage allowing for additional doses from medication vials, which is a key performance metric in the industry.
• EasyPoint retractable needles offer unique safety benefits by allowing activation while the needle is still in the patient, reducing exposure to contaminated needles, differentiating them from manually activated safety needles.
• The company claims its price per unit is competitive or lower than competitors when considering life cycle costs, including disposal, testing, and treatment for needlestick injuries.

Corporate Governance

Legal Proceedings

• Received a $1.9 million settlement payment in May 2025 related to the resolution of litigation with former legal counsel.
• As of March 9, 2026, the company was not a party to or subject to any material legal proceedings.

Related Party Transactions

• The company has a license agreement with its CEO, Thomas J. Shaw, for the exclusive right to manufacture, market, and distribute products utilizing his patented automated retraction technology.
• Under this agreement, Mr. Shaw receives a 5% royalty fee on gross sales of products subject to the license, totaling $3,113,118 in 2025.
• Mr. Shaw also receives 50% of royalties paid to the company by certain sublicensees of the technology.
• The Third Amendment to Technology License Agreement (November 16, 2021) grants Mr. Shaw unilateral rights to terminate or convert the license from exclusive to nonexclusive under certain hostile takeover conditions.
• Mr. Shaw has investment or voting power over 55.7% of the outstanding Common Stock as of March 9, 2026, giving him significant influence over company operations and governance.

Stakeholder Impact

• Shareholders face negative impacts from increasing net losses, declining stock price, and material weaknesses in internal controls. The CEO's 55.7% ownership limits other shareholders' influence and could deter takeovers.
• Employees experienced reductions in force in Q2 and Q3 2025. Increased reliance on the domestic manufacturing workforce due to tariffs is noted, with a commitment to competitive wages and benefits.
• Customers may experience decreased demand due to existing inventory surplus of vaccination products and potential product availability issues if supply chain disruptions or manufacturing shifts are unsuccessful.
• Suppliers face increased reliance on the domestic supply chain for raw materials and components, with potential for increased costs and supply disruptions due to geopolitical conflicts and inflationary pressures.
• Creditors may be impacted by the expected material decline in liquidity over the next 1-3 years, which could affect the company's ability to service debt, although management believes it can meet short-term needs.

Next Steps

• Continue working to lessen the financial impact of tariffs through strategic ordering and shifting more manufacturing to the domestic facility.
• Increase domestic production capacity and efficiency to be cost-competitive with international manufacturers on a pre-tariff basis.
• Find alternate manufacturers for products currently sourced exclusively from China if domestic production is not feasible.
• Enhance controls over the monthly close process and account reconciliations to address identified material weaknesses.
• Continue to evaluate the future impact of the One Big Beautiful Bill Act (OBBBA) for provisions effective after fiscal year 2025.
• Assess the potential impact of ASU 2025-11 and ASU 2025-12 on financial statements and disclosures.
• Attend the Annual Meeting of Shareholders on May 8, 2026.

Key Dates

Recommendation

The company reported an increased net loss for 2025, significant tariff expenses, and identified material weaknesses in internal controls over financial reporting. Liquidity is expected to decline materially in the near term, and the stock price is already a concern for management. While revenue increased, profitability remains elusive, and the competitive landscape with larger players, coupled with ongoing tariff and demand uncertainties, presents substantial headwinds. These factors suggest a negative outlook for investors.

Keywords

Safety medical products, Syringes, Needles, VanishPoint, EasyPoint, Medical devices, Healthcare industry, Tariffs, Domestic manufacturing, SEC filing, 10-K, Financial results, Risk factors, Corporate governance, Intellectual property, Vaccinations, Supply chain, Cybersecurity, Retractable Technologies